Life Sciences Archive » March, 2021

Life Sciences - March, 2021

358 articles

• GAO Says Feds Don't Have Patent Rights To Remdesivir
• Courtroom Shortages Mean Delay For CVS Overcharge Trial
• Oldest Opioid Suit, An MDL Bellwether, Evades Latest Assault
• Calif. Biz Group Blocks New Suits Over Prop 65 Warning
• Drug Price Checker Can Move Ahead With Antitrust Suit
• NJ Justices Lend Support To Pharma Claim Over Racial Slurs
• Mallinckrodt Seeks OK For Up To $35M In Exec Bonuses
• Distributors Can't Duck Nuisance Claim Ahead Of Opioid Trial
• Claims Court Says It Can't Hear Court Office Contract Dispute
• 5th Circ. Ruling Can't Keep Insys Exec Out Of Jail
• Groups Warn COVID IP Waiver Could Hurt Pandemic Efforts
• Illumina Antitrust Case Iced While Patents Challenged
• Union Says Del. Dispensary Refuses To Arbitrate Grievances
• 3 Cybersecurity Questions To Ask Before A Remote Mediation
• Proposed Amendments To Bayh-Dole Regulations Are Vexing
• WebMD Can't Slip Trade Secrets Suit From Argentinian Rival
• 4 Highlights As JPML Gets Earful On McKinsey Opioid Suits
• Merit Medical Can't Dodge Investor Suit Over Acquisitions
• No Jury, No Forfeiture For 'Pharma Bro' Shkreli In FTC Case
• 5-Atty Wilson Sonsini Patent Team Joins Greenberg Traurig
• FTC Challenges Illumina's $8B Deal For Cancer Detection Biz
• Biden's Pick Would Add 1st Black Judge To Fed. Circ.
• Merck Spinoff Organon To Buy Medical Device Co. For $240M
• RJ Reynolds Loses Bid To Strike San Diego Flavor Ban
• Mylan Gets PTAB To Invalidate Sanofi Injector Patent
• Coronavirus Regulations: A State-By-State Week In Review
• Expect Aggressive Health Care Scrutiny From Mass. US Atty
• Union Calls For 11th Circ. To Reinstate Zantac Claims
• Enviro Groups Settle Clean Water Suit Against PPG Inc.
• NJ Dispensary Applicant Can't Bypass Review
• Former Insys Exec Can Delay Prison To Get 2nd Vaccine Jab
• DLA Piper Snags Trial Trio In Dallas
• 1st Circ. Spikes Puerto Rico Age Bias Suit Against Drugmaker
• Generics Cos. Argue For Heritage Bellwether In Antitrust MDL
• A Uniform Mediation Act Primer As States Continue Adoption
• Health Care M&A On The Rise Despite Regulatory Uncertainty
• Judge Jackson Tapped For DC Circ. In 1st Biden Nominations
• Opioid MDL's Tribal Bellwether Dodges Early Drug Co. Attacks
• Arthrex Cleared Of Infringing TriMed Patent After Bench Trial
• McDonald's Taps Boston Scientific Atty As New GC
• Amazon Wants Ex-Worker's Privacy Claim Axed From Pot Suit
• Celebrity Trainer's Row With Greenberg Traurig Revived
• 16 Firms Could Steer IPOs Totaling $3.7B In Short Week
• Pfizer, BioNTech Call IP Suit A 'Burden' On Vaccine Effort
• Insys Brass Knew Opioid Scripts Were Bogus, 1st Circ. Told
• Digital COVID Vaccine Passports Should Be Antitrust-Exempt
• Safeguarding Privileged Communications In A Remote World
• 3rd Circ. Ruling Rejecting Ch. 11 Setoff May Provide Alternative
• Jones Day Fights Ferring's Sanctions Bid Over IP Trial
• Faruqi & Faruqi To Lead Teva Securities Suit Over Kickbacks
• Rite Aid Balks At Opioid MDL Judge's 'Tons Of Money' Remark
• Cash-Hungry Cos. Find Alternative To Volatile Markets
• Novartis Says Chair Contradicted Admissions In FCA Deal
• Mylan Settles Out Of Diabetes Drug Patent Fight At PTAB
• Insys Exec Says 5th Circ. Ruling Should Keep Her Out Of Jail
• Perkins Coie Land-Use Head Sees 4 Active Sectors Amid Virus
• Health Hires: Hooper Lundy, ClearPoint Neuro, Cue Health
• 4 Areas Of Cyberattack Vulnerability For Law Firms
• PTAB Mulls Apple's Fight Over Health Monitoring Patent
• Hologic Tells Justices Assignor Estoppel Is Settled Law
• Feds Urged To Use Moderna Vaccine Patent To Expand Access
• Cherokees Can't Widen Opioid Discovery, Companies Say
• PTAB To Review University Of Calif. Ocular Blade Patent
• Supplement Co. Hit With False Ad Case Over Weight Loss Pill
• Corteva, DuPont Aim To Dodge NJ Water Supplier's PFAS Suit
• US Ranks 2nd In Global Patent Protection For 3rd Year
• Mitsubishi Beats Bid To Invalidate Diabetes Drug Patents
• Duke Hit With Copyright, TM Suit Over Diagnostic Tool
• Bain-Backed Cleaning Products Co. Misses Bar In $692M IPO
• Real Estate Rumors: Blackstone, Chelminsky, Prologis
• Fed. Circ. Denies Another Stanford Genetics Patent Over Alice
• NYC Settles Environmental Dept. Workers' OT Suit For $332K
• How To Help Your Witnesses Overcome Hindsight Bias
• Lundbeck Loses EU Appeal Over €146M 'Pay For Delay' Fine
• Oramed Investor Suit Seeks To Claw Back Stock Awards
• Reps Urge Biden To Make COVID Vax Mandatory For Military
• 3rd Circ. Won't Touch Clinic's Win In Worker's ADA Suit
• Ex-Allied BioScience CEO Can't Nix Claim He Held IP Hostage
• Purdue, Sackler Opioid Suits Paused For Another Month
• Pharma Industry Can Expect More Scrutiny From State AGs
• HHS Nominee Clears Senate In Transgender Milestone
• Pot Trade Group Can Enter Maine Cannabis License Dispute
• 7th Circ. Should Find Patent Thickets Aren't Anti-Competitive
• GSK Says No Link Between Zofran, Defects Undermines MDL
• Vast Trove Of Big Pharma's Opioid Records Launches Online
• St. Jude Medical Beats Patent Suit Over Catheter Method
• NJ 'Reply All' Ethics Opinion Brings New Pitfalls For Attorneys
• McCarter & English Gets Mixed Ruling In Fight With Ex-Client
• Eli Lilly Loses $10M Fee Bid Over Genentech's Dropped IP Suit
• J&J Seeks High Court Holy Grail: A Cap On Punitive Damages
• Eye Diagnostic Co. Blocks Rival's Software Launch In IP Fight
• Generics MDL Special Master Says Calif. AG Merits Sanctions
• Feds Don't Want Hospital Groups In Pharma Discount Fight
• Sacklers Say No Ch. 11 Deal Without Injunction Extension
• Federal Gov't Can Learn From State Drug Pricing Efforts
• Fla. Woman Asks 11th Circ. To Revive Pelvic Mesh Claims
• Boston Scientific To Pay $188M Over Mesh False Ad Claims
• Pomerantz, Rosen Fight In Del. To Lead Walmart Investor Suit
• 3 Arthrex-Adjacent High Court Cases Could Affect PTAB's Fate
• 11th Circ. Rips FDA's 'Invisible Ink' Interpretation Of Drug Act
• Mass. Panel Partially Revives Neurologist's Retaliation Suit
• Boston Scientific Can't Duck Implant Wrongful Death Suit
• Coronavirus Regulations: A State-By-State Week In Review
• AbbVie Says Rival Used Stolen Trade Secrets To Copy Drug
• 250 Researchers, Orgs Urge WTO To Back COVID IP Waiver
• FDA Cracks Down On CBD 'Pain Relief' Products
• McKinsey To Pay Nevada $45M To End Opioid Marketing Case
• NY Hospitals Not Liable In Malpractice Suit Over Boy's Killing
• Local Gov'ts Say New $650M Bayer Deal Fixes Funds Timeline
• Mallinckrodt To Pay $267M Over Maine Mercury Contamination
• White FDA Scientist's Race-Bias Suit Comes Up Short
• States Say Time Has Come To Let Sackler Suits Proceed
• 3 Biotech Firms Join Packed Calendar Of At Least 19 IPOs
• Conn. Firefighter Axed Over Pot Use Has ADA Suit Tossed
• Judging A Book: Bibas Reviews Rakoff's 'Why The Innocent Plead Guilty'
• High Court Won't Hear Generic MS Drug Patent Challenge
• Couples Aim To Revive $83M J&J, Bard Mesh Verdicts
• 3 Firms Seek $4M For CytoDyn Stock Award Suit Settlement
• Axogen Stock Offering Suit Axed Again, But Appeal Looms
• Greenberg Traurig Adds Jones Day IP Atty In Los Angeles
• Novartis Names Longtime AbbVie Atty As CLO
• AstraZeneca Calls Virus Vaccine 'Highly Effective'
• As AG Takes Wheel At HHS, Biden Faces Rocky Legal Road
• Omnicare, CVS Can't Toss FCA Suit Over Prescription Scheme
• Allergan Must Face Breast Implant, Class Claims In MDL
• Biotech CEO Lied About Home COVID-19 Test, Investors Say
• Sanofi Says Insulin Pen Buyers Can't Expand Antitrust Case
• Bayer Skips High Court Review Of $21M Roundup Verdict
• 3rd Circ. Won't Cut McKesson's Debt To Obesity Drug Co.
• HHS Halts 'Ticking Timebomb' Sunset Rule After Being Sued
• Immunomedics Broke Exit Deal With Founder, Chancery Told
• Sackler Act Would Ban Release Of Nondebtor Gov't Claims
• Breaking IP Barriers: Q&A With White & Case's Anita Varma
• Mallinckrodt Investor Can't Call Meeting To Replace Board
• DOJ Says Atty Wall Can't Fix Morgan Lewis, Glenmark Conflict
• Justices Told Arthrex Win Means USPTO Can't Cancel Patents
• 3 Biotech Firms, Cannabis REIT Price IPOs Totaling $758M
• Health Hires: Orrick, K&L Gates
• For Law Firm Digital Marketing, Less Is Sometimes More
• Must Pharmacists Investigate All Prescriptions For Fraud?
• Indian Biopharma Valued At $350M In Funding Rounds
• Investors Launch Suit Over Reckitt's $1.4B Suboxone Deal
• Pillsbury, Ropes & Gray Steer Health Tech Co. $1.2B Go-Public
• Opioid Distributors Argue 'Nuisance' Trial Theory Is Nonstarter
• AbbVie Asks High Court To Review Sham Litigation Exception
• AbbVie Loses Judge-Switch Bid In Humira Kickback Battles
• Walgreens Inks $3.3M Deal Over Pharmacy Tech Wage Claims
• Justices Asked To Undo 'Dangerous' Patent Case Ruling
• Feds Charge Fecal Testing Startup Founders With Fraud
• Deals Rumor Mill: Chubb, AbbVie, NMC Health
• GW Pharmaceuticals Investors Sue To Stop $7.2B Acquisition
• Drug Co. Owed Defense In Opioid Suits, Ohio Justices Told
• Chinese IoT Platform Developer Leads 4 IPOs Topping $1.5B
• Paul Weiss, Davis Polk Rep Insurtech's Planned $490M IPO
• Mintz Adds Haug Litigation Partner With Life Sciences Chops
• Inventors, Tech Are Taking The Brunt Of Alice Axes
• Unvaccinated Insys Exec Asks For Another Prison Delay
• Climate Change Plaintiffs Are Getting Creative
• Health Tech Co. Can't Boot Klamann From ERISA Arbitrations
• Coppertone Buyers, Bayer Ink $2.25M Deal In False Ad Suit
• Levi & Korsinsky Earns $2.1M For Illumina Shareholder Suit
• Okla. Dodges Suit Over Pot License Residency Rules
• PTAB Reveals Route To IPR Institution Denial In Parallel Cases
• Calif. AG Wins Senate Confirmation To Lead HHS
• 2nd Circ. Says Chinese Regs Key To Vitamin Price-Fixing Case
• Pharmacies Rip FDA Bid To End Compound Drugs Reg Case
• Immunocompromised Atty Gets IP Trial Moved To Sept.
• UK Looks Determined To Grab A Larger Share Of SPACs
• Calif. Must Share Rx Data With Walgreens In Opioid Row
• Hand Sanitizer Buyers Want Cert. In CVS False Ad Suit
• States Push New Bellwether Generic Drug Price-Fixing Case
• Aceto Investors Can't Resurrect Securities Suit
• Teva Sues BioMarin In UK Over Genetic Disorder Drug Patent
• Ex-Theranos CEO Holmes' Trial Delayed Due To Pregnancy
• AbbVie Denies Judge-Shopping In Humira Kickback Cases
• Eli Lilly Wins Bid To Block HHS Drug Discount Rule
• Crest Buyers Say They Were Duped By Charcoal Toothpastes
• McKinsey Opioid Deal With NY AG Approved Amid Objections
• PhRMA Can't Get Minn. Insulin Pricing Law Overturned
• Drug Return Co., Execs Want 3rd Circ. To Undo $94M Verdict
• Purdue's Ch. 11 Plan Hangs On Sackler Liability Question
• FTC Leads International 'Rethink' Of Pharma Merger Reviews
• Fox Rothschild Gets Copyright Pro From Taft Stettinius
• AstraZeneca Resets FTC Review Clock For $39B Alexion Deal
• Coronavirus Regulations: A State-By-State Week In Review
• Express Scripts Fights Workers' Cert. Bid In 'Manager' OT Suit
• Protecting Trade Secrets In The Remote Workplace
• Strategies For Fighting Back Against A Rambo Litigator
• Generics Call Alcon Glaucoma Drug Obvious As Trial Begins
• Teva Sues BMS, Pfizer Over UK Blood Thinner Patents
• Purdue Files Ch. 11 Plan That Draws Criticism From State AGs
• Astellas Aims To Block Generic In Incontinence Drug IP Fight
• US Cos.' Patent Filings In Europe Dropped 4% Amid Pandemic
• As Justices Mull Abortion Showdown, Circuit Split Deepens
• Biotech Co. Says It Never Lied About Its COVID Vaccine Work
• J&J Unit Wins Another Shot At Medical Stapler IP Amendment
• Glenmark Rips DOJ's 'Misplaced' Morgan Lewis Conflict Claim
• Spinal Device Co. Wins Ban Against Rival, But Must Pay Bond
• Becton Beats Antitrust Suit After 7th Circ. Revival
• Hearing Aid Co. Settles Workers' Stock Plunge Suit
• 8th Circ. Told $75M Dicamba Ruling Riddled With Errors
• Vitamin C Price-Fixing Case: Round 2 At The 2nd Circ.
• Cooley-Led DigitalOcean Leads 5 Planned IPOs Totaling $2B
• GameStop Frenzy No Reason To Jettison Securities Theory
• Court Erred In Barring Late DOJ Intervention In FCA Case
• Ill. City Wants Acthar Cases In MDL, Out Of Bankruptcy
• DLA Piper, Sidley Guide $1.8B Deal For Disease Testing Biz
• Acer Therapeutics Derivative Settlement Gets Initial Nod
• Law Firm Admonished For 'False' Ads In Gilead HIV Drug Suit
• Fed. Circ. Affirms Letting J&J Reveal Manufacturer In IP Row
• Health Hires: Holland & Knight, AavantiBio
• Fed. Circ. Calls Route To PTAB Denial Appeals 'Very Narrow'
• Minn. AG's Insulin Suit Against Sanofi, Eli Lilly Gutted
• Convertible Bond Offerings Ride To New Heights
• Charting A Year Of The Biggest COVID Scams Cited By FDA
• Pool Equipment Biz Raises $685M To Lead IPO Pack
• NJ Court Skeptical Of FCA Claims Against Gilead, Shire
• Justices Told Fed. Circ. Muddied Inventorship Law In IP Row
• Pharma Co. Seeks J&J Virus Vaccine License — Or Else
• Ex-Theranos CEO Holmes Pregnant, Wants July Trial Delayed
• Nev. Justices Say Insurer Can Recoup Costs From Implant Co.
• ITC Keeps Probe Of Russian, Indian Polymer On Track
• Real Estate Rumors: Hersha, Wayne Rosen, Oaktree
• Skadden, Kirkland Guide Co.'s $1B Sale Of Medical Device Biz
• 1 Year Into Pandemic, It's Time To Rethink Law Firm Billing
• LG Chem Beats Suit Over Genetic Database License, For Now
• The Defining Pandemic Moments For Health And Life Sci Attys
• Arnold & Porter Accused Of Conflicts In Mallinckrodt Ch. 11
• Smoker's Wife Can't Collect $1.3M More From Philip Morris
• WTO Fails To Reach Deal On COVID IP Waiver Proposal, Again
• Ohio Ordered To Respond To Pot Grower's Expansion Request
• Senate OKs Drug Exclusivity Change To Boost Generics
• Why A Surge Of COVID Securities Suits Hasn't Happened
• What One Firm's Filings Reveal About Labeling Class Actions
• What Companies Should Know About SIGPR Oversight
• Hashing Out IP And Legality Questions On Delta-8 THC
• Supplement Maker Must Face Trimmed Claims Of Harm
• How Biden's Leadership Picks Will Shape Health Priorities
• Fed. Circ. Axes Stanford's Genetic Analysis Patent As Abstract
• Rogue High Court Citation May Spark Legal Writing Changes
• Dermatology Biz Says UK Lab Breached $1M Licensing Deal
• Deals Rumor Mill: Shutterfly, Cooper, Apax Partners
• Trading Firm Says 3rd Time's The Charm For $3.6M Award
• Verano, Harvest Hit With RICO Suit By Ex-Worker After Arrest
• Ariz. Pot Co. Ends Extortion Suit Against Exec Over License
• Mass. Federal Judge Is Latest To Take Senior Status
• Vanda Pharma Can't Nix Investors' Off-Label Fraud Suit
• Scotts, Acreage Were Top Spenders In NJ Legal Pot Effort
• Mallinckrodt Adds Senior Lenders To Ch. 11 Plan Supporters
• FDA Scolds Drug Co. Over Kardashian Promo On 'The View'
• House Sends $1.9T Virus Relief Package To Biden
• Pleading Tortious Interference Claims In Calif. After Ixchel
• The Case For Diversity In Internal Investigation Teams
• Providence Health & Services CLO Dies At 53
• Trump's HHS Left 'Ticking Timebomb' For Old Rules, Suit Says
• Westco Workers Win Class Cert. In 'Secret' Pension Suit
• J&J Aims To Sink $117M Talc Verdicts With 'Seismic' Impact
• CBD Co. Zynerba, Investors Aim To Settle Drug Trial Claims
• Pot Co. Wins $15M In Brawl Over Columbia Care Fla. License
• Freezer Co. Denied Early Win In Suit Over Destroyed Embryos
• Teva Investors Win Class Cert. In Securities Suit
• Coronavirus Regulations: A State-By-State Week In Review
• Calif. Enviro Group Wins Water Well Fight On Appeal
• Fed. Circ. Backs Becton PTAB Wins On 2 Drug Dosing Patents
• WTO Chief Calls Unequal Vaccine Delivery 'Unconscionable'
• Opioid Distributor, Execs Can't Escape DOJ Indictments
• Key Insights From DOJ's 2020 Fraud Enforcement
• 'No Room For Error': Novavax Deal Hits Home For Ropes Atty
• COVID-19 Drugmaker Eli Lilly Appoints New Compliance Chief
• Ferring Urges Sanctions For Jones Day Over 'Forced' IP Trial
• McKinsey Seeks New MDL As Opioid Headaches Worsen
• Justices Told Thyroid Drug Patent Ax Flouts Global Pact
• NY AG Opioid Trial Now Set For June Amid Virus Concerns
• Fed. Circ. Won't Undo Amgen's Cancer Drug IP Win
• Ex-Med Tech Exec Cops To Obstructing Feds' Purdue Probe
• Sandoz Fights FDA Exclusivity For Sanofi Blockbuster
• Ariz. High Court Allows Costco Privacy Suit To Proceed
• ​​​​​​​Cal State Univ. Gets $2.9M PAGA Safety Fine Axed On Appeal
• Food-Ordering Co. Olo Tops 4 IPO Launches Totaling $706M
• Sens. Tell USPTO That Patent Eligibility Rules Hurt Innovation
• Merck Can't Escape Union OT Back Pay Bid In Arbitration Row
• DOJ Worried Over Morgan Lewis Generic Price-Fixing Conflict
• Health Info Blocking Rule Creates Opportunities For Research
• 5 Ways Outside Counsel Can Impress Their Clients
• Moderna Taps Ex-Novartis CLO As Top Lawyer
• Overlooked PTAB Cases: Raising Nonobviousness Evidence
• Attys Seek To Delay $2B Roundup Deal Hearing
• GW Pharma Wants Out Of Canopy's CBD Patent Dispute
• AdventHealth Reaches Deal On COVID-19 PPE Fraud Claims
• Senate Approves $1.9T Virus Relief Plan With Changes
• Another CBD Co. Gets Consumer Suit Halted Over FDA Delay
• Roundup Claimants Slam 'Frankenstein-ian' $2B Bayer Deal
• Walgreens Settles PAGA Off-Duty Break Suit For $6.8M
• Opioid Litigation Is Prying Open Vaults Of Big Pharma Secrets
• US Extends China Tariff Cuts On Virus Response Gear
• Billionaire Frost, OPKO Execs Sued Over Leadership Diversity
• How Drug Cos. Can Adapt To New Reference Pricing Rules
• Health Hires: Mintz, Apria, DBV Technologies
• Declaratory Judgments Unavoidable For Biosimilar Applicants
• Landmark NY Opioid Trial Delayed Amid Virus Concerns
• DOJ's 'Troubling' Theory Gains Walmart Allies In Opioid Case
• FDA Tells Osteopath To Stop Marketing Fake COVID-19 Cures
• Pot Co. Says Trade Group Has No Stake In Maine License Row
• FDA Seeks Win In Suit Over Compounded Drug Agreements
• Dust Spray Maker Can't Dodge Suit Over DUI Death
• 'Pharma Bro' Shkreli Hit With 1st Private Antitrust Suit
• NH High Court Says Insurers Must Cover Workers' Medical Pot
• Teva Faces EU Antitrust Probe Over MS Drug Patent Strategy
• Germ-X Maker Beats Hand Sanitizer False Ad Suit, For Now
• Deals Rumor Mill: Robinhood, Flipkart, Permira
• 2 Firms Guide Amgen's $1.9B Deal For Cancer Drug Biz
• Ethics Tips For Attorneys Telecommuting Across State Lines
• Emory Says Ex-Worker's 2 Discrimination Suits Split Claims
• 1st Circ. Says Abbott Doesn't Owe $1M Age Bias Verdict
• CEO In $150M Opioid Scheme Hit With 15-Year Sentence
• Pharma Cos. Held In Contempt In Trade Secrets Case
• Del. Justices Reverse GSK's $57M Lupus Drug Patent Loss
• Latham, Ropes Guide $1.07B Boston Scientific-Lumenis Deal
• NY Opioid Trial Defendants Want New COVID-19 Delay
• Reckitt Benckiser Coughs Up $53M To End False Ad Suit
• Okla. Seeks 19-Year Extension To J&J $465M Opioid Judgment
• Senate Caucus Presses For New Pot Research Regulations
• J&J Blasts 'Tainted Process' In Imerys Ch. 11 Case
• AstraZeneca Beats Mylan Challenge To Inhaler IP's Validity
• Abbott Labs Sales Director's Age Bias Case Teed Up For Trial
• 6 Ways Legal Employers Can Help Pandemic-Weary Parents
• Health Cos. Can Reduce FCA Risk By Leveraging Data
• Charlotte's Web Signs Deal To Enter Pot Biz Upon Legalization
• Questions Loom About DOJ Dismissal Power In FCA Suits
• 10th Circ. Says Nurse Must Face Wrongful Death Suit
• Big Tobacco Wins 3rd Delay Of Graphic New Warning Labels
• After J&J-Merck Deal, Biden Vows Vaccines For All By May 31
• Supreme Court Urged To Rein In Use Of Assignor Estoppel
• Hospital Groups Want To Join Fight Over Drug Discount Rule
• Chamber Urges WTO Not To Entertain Vaccine IP Waivers
• Fla. Sens. Introduce Cannabis Legalization, Taxing Proposals
• Insys Founder Says 'Spillover Prejudice' Warrants New Trial
• Teva, Mylan Back Plan For New Bellwether In Price-Fix MDL
• J&J Urges High Court To Nix $2.1B Talc Verdict
• AdventHealth, Atty Settle In Fraud Suit Over $57M PPE Deal
• 3 Degrees Of Legalization Show True Prevalence Of Cannabis
• Va. Legislature Approves Recreational Cannabis, Tax On Sales
• Alsup Won't Budge On Sanction For Ex-MLB Player's Atty
• J&J, Bard $83M Pelvic Mesh Verdicts Overturned
• Biotech Exec Admits Insider Trading On Dimension Deal Talks
• Coronavirus Regulations: A State-By-State Week In Review
• Remote Working Tips For Lawyer Trainees And Their Firms
• PQ Group Offloads Performance Chemicals For $1.1B
• Ex-Amazon Worker Says Medical Marijuana Use Got Him Fired
• SPACs Power Another Record-Breaking Month For IPOs
• Justices Suggest PTAB Will Survive, But With More Oversight
• FTC Alums Join Gibson Dunn's Antitrust Group As Partners
• Otterbourg Adds New York Deals Pro From Akerman
• EpiPen Ruling Could Embolden Private Anti-Kickback Claims
• Fed. Circ. Backs $173M Bayer Patent Win On Hemophilia Drug
• J&J Brushes Off ERISA Suit Over Asbestos In Baby Powder
• 3 Firms Direct $1.55B Sale Of Perrigo Unit To PE Firm
• Purdue Promises Ch. 11 Plan In 2 Weeks